Facebook Pixel In India, A Gold Rush For Weight Loss Drugs | Mint Hyderabad - newspaper - Lisez cet article sur Magzter.com
Passez à l'illimité avec Magzter GOLD

Passez à l'illimité avec Magzter GOLD

Obtenez un accès illimité à plus de 9 000 magazines, journaux et articles Premium pour seulement

$149.99
 
$74.99/Année

Essayer OR - Gratuit

In India, A Gold Rush For Weight Loss Drugs

Mint Hyderabad

|

June 20, 2025

Lured by a global rage, Indian drug makers are eyeing fat profits from GLP-1 drugs

- T. Surendar & Jessica Jani

MUMBAI In late May, Dr. Reddy's Laboratories, a pharmaceutical company from Hyderabad, sprang a surprise. It filed a patent challenge against Novo Nordisk, a Danish company, for its popular weight loss drug semaglutide.

Novo Nordisk filed for two patent applications in India—in 2006, which expired in September 2024, and another in 2007, which is set to expire in March 2026. Dr. Reddy's has challenged the second patent, contending that it lacks novelty.

Pharma companies often file follow-on patents with claims of modifications to the original compound and its derivative forms. The follow-on patents allow drug developers to extend their market monopoly and halt generic competition for longer. Generic versions are cheaper copies of the original drug.

Dr. Reddy's, obviously, is in a hurry to launch a generic version. A win for the company will upend the plans of more than a dozen local pharmaceutical firms, all of whom are eyeing a slice of the estimated $25 billion Indian weight loss market.

No prescription drug in recent memory has captured the imagination of Indian patients as much as semaglutide. Or for that matter globally. In 2024, sold under three brand names—Ozempic, Wegovy and Rybelsus—semaglutide is the second most prescribed drug in the world, notching sales of $29 billion annually.

A more recently launched competing brand, Mounjaro, by US-headquartered drug maker Eli Lilly, grew 123% in 2024 to $11.5 billion and is already among the top 10 drugs in the world, according to Drug Discovery & Development, a pharmaceutical industry news website.

"It's a big opportunity. It's a product that comes once in a while in the pharma cycle, and perhaps a product that people are a lot more aware of, much before its launch," Umang Vohra, managing director and global CEO of Cipla, told journalists during an interaction last month.

PLUS D'HISTOIRES DE Mint Hyderabad

Mint Hyderabad

Mint Hyderabad

A new grammar to challenge Tamil film

Members of the Problematic Family, which premiered at the Berlinale, is a striking, experimental debut film from R. Gowtham

time to read

3 mins

February 26, 2026

Mint Hyderabad

Mint Hyderabad

Uranium supply deal likely during Carney’s India visit

Cameco CEO Tim Gitzel to be part of the business delegation accompanying Canadian PM

time to read

2 mins

February 26, 2026

Mint Hyderabad

Can ABB surf the order wave?

ABB India's order inflow rose by a sharp 52% year-on-year in Q4CY25 amid early signs of demand improvement.

time to read

2 mins

February 26, 2026

Mint Hyderabad

Mindspace, Chalet ink pre-lease pact

Mindspace Business Parks REIT, which owns and develops Grade A office assets, on Wednesday said it has pre-leased a 530,000 sq. ft building at its Mindspace Madhapur campus in Hyderabad to Chalet Hotels Ltd for a luxury hotel project.

time to read

1 min

February 26, 2026

Mint Hyderabad

Mint Hyderabad

Govt's goal is to remove fear of 'tariff wall' in calibrated manner, says FM

Union finance minister Nirmala Sitharaman said on Wednesday the government's goal is to completely remove the fear of a “tariff wall” around the Indian market, but it has to be carefully calibrated and cannot be a hurried exercise.

time to read

2 mins

February 26, 2026

Mint Hyderabad

US duty stings solar stocks; sector may escape unhurt

Centre won't step in on behalf of affected firms, says solar makers have legal recourse

time to read

1 mins

February 26, 2026

Mint Hyderabad

Mint Hyderabad

CHASING 12% EQUITY RETURNS? LONG-TERM INVESTING ISN'T JUST ABOUT A NUMBER

Most investors enter equity mutual funds expecting an annual average return of about 12%.

time to read

3 mins

February 26, 2026

Mint Hyderabad

Why midscale is the sweet spot in India’s hotel market

Largest growth to be in the midscale hotel category, in a wider set of cities, even as costs rise

time to read

2 mins

February 26, 2026

Mint Hyderabad

Digital rupee pilot for food subsidy

In a significant shift in the way food subsidies are delivered, the government will launch a central bank digital currency (CBDC)-based pilot under the Pradhan Mantri Garib Kalyan Anna Yojana (PMGKAY) in Puducherry on 26 February.

time to read

1 min

February 26, 2026

Mint Hyderabad

Mint Hyderabad

PM Modi at Knesset: India backs Gaza peace initiative

PM called for sustained and coordinated global efforts to counter terrorism

time to read

1 mins

February 26, 2026

Listen

Translate

Share

-
+

Change font size